NCT01549834

Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 434 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 55 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This is an efficacy and safety study evaluating a new treatment for subjects with mild to moderate Alzheimer's disease.

Detailed description

This is a Phase 2 study designed to evaluate the efficacy and safety of ABT-126 in approximately 420 adults with mild to moderate Alzheimer's disease who are taking stable doses of acetylcholinesterase inhibitors. Subjects will be randomized to one of two ABT-126 dose arms or placebo for a 24-week treatment period.

Conditions

• Alzheimer's Disease

Interventions

Type	Name	Description
DRUG	ABT-126	Low Dose
DRUG	ABT-126	High Dose
DRUG	placebo	Placebo

Timeline

• Start date: 2012-03-01
• Primary completion: 2013-10-01
• Completion: 2013-10-01
• First posted: 2012-03-09
• Last updated: 2014-10-31

Locations

43 sites across 7 countries: United States, Canada, France, Germany, Greece, South Africa, United Kingdom